Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Cash & Current Investments (2016 - 2025)

Regenxbio has reported Cash & Current Investments over the past 12 years, most recently at $230.1 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $230.1 million for Q4 2025, down 1.97% from a year ago — trailing twelve months through Dec 2025 was $230.1 million (down 1.97% YoY), and the annual figure for FY2025 was $230.1 million, down 1.97%.
  • Cash & Current Investments for Q4 2025 was $230.1 million at Regenxbio, down from $274.2 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for RGNX hit a ceiling of $457.4 million in Q4 2021 and a floor of $230.1 million in Q4 2025.
  • Median Cash & Current Investments over the past 5 years was $327.6 million (2023), compared with a mean of $330.0 million.
  • Biggest five-year swings in Cash & Current Investments: soared 57.88% in 2021 and later fell 24.51% in 2023.
  • Regenxbio's Cash & Current Investments stood at $457.4 million in 2021, then dropped by 20.29% to $364.6 million in 2022, then fell by 24.51% to $275.3 million in 2023, then dropped by 14.74% to $234.7 million in 2024, then fell by 1.97% to $230.1 million in 2025.
  • The last three reported values for Cash & Current Investments were $230.1 million (Q4 2025), $274.2 million (Q3 2025), and $323.3 million (Q2 2025) per Business Quant data.